BACKGROUND: Atherosclerotic renovascular disease (ARVD) is associated with high rates of coronary events and predicts mortality among patients with coronary artery disease (CAD). However, the impact of coronary atherosclerosis on renal outcomes after revascularization of ARVD is unclear. We hypothesized that CAD negatively impacts renal functional outcomes among patients with ARVD undergoing renal artery revascularization. METHODS: Patients with ARVD who underwent echocardiography at Mayo Clinic, Rochester, Minnesota, USA between 2004 and 2012 were identified retrospectively and included if they had ejection fraction more than 50%. Renal and overall outcomes were compared among atherosclerotic renovascular disease patients with coronary artery disease (ARVD-C, n = 75) and without coronary artery disease (ARVD, n = 56), within 1 year from initial revascularization and included blood pressure control, renal function, and incident cardiovascular/cerebrovascular events. RESULTS: Degree of renal artery stenosis was similar in both groups. ARVD-C had higher prevalence of diabetes, peripheral artery disease (PAD), and cerebrovascular disease, and lower baseline renal function. Risk of developing end-stage renal disease was higher in ARVD-C (11 vs. 2%, P = 0.05). Despite better control of blood pressure and cholesterol levels, renal function postrevascularization worsened in 15% of ARVD-C compared with 2% of ARVD (P = 0.01). Differences in clinical outcomes remained statistically significant after adjustment for covariables, including sex, baseline blood pressure, renal function, underlying diabetes, cholesterol levels, and medications. Similar differences in clinical outcomes were also associated with PAD and cerebrovascular disease. CONCLUSION: CAD in patients with ARVD is a predictor of worse outcomes after renal revascularization, likely reflecting diffuse atherosclerotic disease. Further studies are needed to develop strategies to manage patients with vascular comorbidities and improve their outcomes.
BACKGROUND:Atherosclerotic renovascular disease (ARVD) is associated with high rates of coronary events and predicts mortality among patients with coronary artery disease (CAD). However, the impact of coronary atherosclerosis on renal outcomes after revascularization of ARVD is unclear. We hypothesized that CAD negatively impacts renal functional outcomes among patients with ARVD undergoing renal artery revascularization. METHODS:Patients with ARVD who underwent echocardiography at Mayo Clinic, Rochester, Minnesota, USA between 2004 and 2012 were identified retrospectively and included if they had ejection fraction more than 50%. Renal and overall outcomes were compared among atherosclerotic renovascular diseasepatients with coronary artery disease (ARVD-C, n = 75) and without coronary artery disease (ARVD, n = 56), within 1 year from initial revascularization and included blood pressure control, renal function, and incident cardiovascular/cerebrovascular events. RESULTS: Degree of renal artery stenosis was similar in both groups. ARVD-C had higher prevalence of diabetes, peripheral artery disease (PAD), and cerebrovascular disease, and lower baseline renal function. Risk of developing end-stage renal disease was higher in ARVD-C (11 vs. 2%, P = 0.05). Despite better control of blood pressure and cholesterol levels, renal function postrevascularization worsened in 15% of ARVD-C compared with 2% of ARVD (P = 0.01). Differences in clinical outcomes remained statistically significant after adjustment for covariables, including sex, baseline blood pressure, renal function, underlying diabetes, cholesterol levels, and medications. Similar differences in clinical outcomes were also associated with PAD and cerebrovascular disease. CONCLUSION: CAD in patients with ARVD is a predictor of worse outcomes after renal revascularization, likely reflecting diffuse atherosclerotic disease. Further studies are needed to develop strategies to manage patients with vascular comorbidities and improve their outcomes.
Authors: S Kuroda; N Nishida; T Uzu; M Takeji; M Nishimura; T Fujii; S Nakamura; T Inenaga; C Yutani; G Kimura Journal: Stroke Date: 2000-01 Impact factor: 7.914
Authors: S Shintani; T Murohara; H Ikeda; T Ueno; T Honma; A Katoh; K Sasaki; T Shimada; Y Oike; T Imaizumi Journal: Circulation Date: 2001-06-12 Impact factor: 29.690
Authors: D Orlic; J Kajstura; S Chimenti; F Limana; I Jakoniuk; F Quaini; B Nadal-Ginard; D M Bodine; A Leri; P Anversa Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: Julian R Wright; Ala'a E Shurrab; Ching Cheung; Steven Waldek; Donal J O'Donoghue; Robert N Foley; Hari Mamtora; Philip A Kalra Journal: Am J Kidney Dis Date: 2002-06 Impact factor: 8.860
Authors: Charanjit S Rihal; Stephen C Textor; Jerome F Breen; Michael A McKusick; Diane E Grill; John W Hallett; David R Holmes Journal: Mayo Clin Proc Date: 2002-04 Impact factor: 7.616
Authors: Alfonso Eirin; Xiang-Yang Zhu; Behzad Ebrahimi; James D Krier; Scott M Riester; Andre J van Wijnen; Amir Lerman; Lilach O Lerman Journal: Cell Transplant Date: 2014-11-21 Impact factor: 4.064
Authors: Alfonso Eirin; Xiang-Yang Zhu; Christopher M Ferguson; Scott M Riester; Andre J van Wijnen; Amir Lerman; Lilach O Lerman Journal: Stem Cell Res Ther Date: 2015-01-19 Impact factor: 6.832
Authors: Dong Sun; Alfonso Eirin; Xiang-Yang Zhu; Xin Zhang; John A Crane; John R Woollard; Amir Lerman; Lilach O Lerman Journal: Kidney Int Date: 2014-10-22 Impact factor: 10.612
Authors: Xiao-Jun Chen; Alfonso Eirin; Garvan C Kane; Sanjay Misra; Stephen C Textor; Amir Lerman; Lilach O Lerman Journal: Int J Hypertens Date: 2019-01-30 Impact factor: 2.420